Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

작성일 2026-06-19  |  큐라클관리자

본문

https://www.globenewswire.com/news-release/2026/06/18/3314508/0/en/memento-medicines-launches-with-93-million-series-a-financing-to-advance-tie2-agonist-and-vegf-inhibitor-bispecific-antibody-therapy-for-retinal-diseases.html

첨부파일